Oventus Medical (ASX:OVN) - Chairman, Sue MacLeman (centre left) - The Market Herald

" Oventus Medical (ASX:OVN) eyes $5M placement to strengthen balance sheet

Sleep apnoea specialist Oventus Medical (OVN) has received firm commitments to undertake a $5 million placement.
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald

" Telix Pharmaceuticals (ASX:TLX) commences prostate cancer clinical trial

Telix Pharmaceuticals (TLX) has been given the green light to commence a phase three clinical trial of its targeted therapy candidate TLX591 in
Bod Australia (ASX:BDA) - CEO, Jo Patterson - The Market Herald

" Bod Australia (ASX:BDA) records highest ever month of MediCabilis sales

Bod Australia (BDA) has recorded its highest-ever month of medicinal cannabis sales, filling 1789 MediCabilis prescriptions in April.
Prescient Therapeutics (PTX) -CEO & Managing Director, Steven Yatomi - The Market Herald

" Prescient Therapeutics (ASX:PTX) signs new research agreement with Peter MacCallum Cancer Centre

Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre to advance its next-generation CAR-T programs.
PolyNovo (ASX:PNV) dispatches first NovoSorb BTM order in Europe

" Polynovo (ASX:PNV) appoints Joshua Cheetam as Director of Research and Development

PolyNovo (PNV) has appointed Dr Joshua Cheetam as Director of Research and Development.
Immutep (ASX:IMM) - CEO, Marc Voigt - The Market Herald

" Immutep (ASX:IMM) progresses multiple efti trials

Immutep (IMM) has provided an update on its clinical and preclinical programs.
The Market Herald Video

" Regeneus (ASX:RGS) secures $4.5 M for osteoarthritis trials

Clinical-stage regenerative medicine company Regeneus (RGS) has secured up to $4.5 million in a three-stage placement of the company’s shares to New Lif…
Rhythm Biosciences (ASX:RHY) brings ColoSTAT trial to Queensland

" Noxopharm (ASX:NOX) cancer trial set to open

Clinical-stage drug development company Noxopharm (NOX) is preparing to open a CEP-2 study into its Veyonda drug candidate.
Nyrada (ASX:NYR) - CEO, James Bonnar - The Market Herald

" Nyrada (ASX:NYR) pockets $1M tax rebate for 2020 drug development work

Drug developer Nyrada (NYR) has retreated slightly on the ASX today despite pocketing a million-dollar tax rebate from the Federal Government.
MedAdvisor (ASX:MDR) signs second U.S. agreement with major company

" Medadvisor (ASX:MDR) nets cash for digital U.S. initiatives

Medication management software company Medadvisor (MDR) has secured $5.25 million via a placement and locked in an $11.7 million loan facility.